(HCT). The major limitation of this approach is the slow antibody (Ab) accretion at tumor sites and gradual elimination from circulation. We have used a pretargeted (P) RIT approach employing the high-affinity streptavidin (SA)-biotin system, in which an anti-CD45 Ab-SA conjugate and the radioactive DOTA-biotin compound are administered separately. After maximal accumulation of Ab-SA conjugate in CD45 þ tissues, therapeutic radiobiotin is administered and attaches to the pretargeted Ab-SA conjugate bound specifically to tumor cells, with unbound radiobiotin rapidly excreted by the kidneys. We have evaluated the safety of PRIT using an anti-CD45 Ab-SA conjugate followed by 90 Y-DOTA-biotin combined with fludarabine (FLU), 2 Gy total body irradiation (TBI) and matched allogeneic HCT for patients with advanced acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or high-risk myelodysplastic syndrome (MDS). Seven patients received trace labeled, dosimetric infusions of 0.7 mg/kg anti-CD45 Ab-SA followed 48 hours later by 1.3 mg/m 2 of 111 In-DOTA-biotin (5-10 mCi). consecutive days followed by TBI at a dose of 2 Gy (6-7 cGy/min) and then infusion of >2 x 10 6 CD34-expressing peripheral blood stem cells/kg body weight. Two grade 3 gastrointestinal adverse events (enterocolitis, typlitis) were identified as unexpected and considered possibly related to PRIT, with the only grade 4 event being cytopenias that are expected during HCT. No participants were withdrawn from the study due to toxicities. One of the 5 high-risk AML/MDS patients enrolled remains alive in complete remission a year after protocol treatment. The other 4 patients died of progressive disease with a median time to relapse of 28 days (range 12-155).
is administered and attaches to the pretargeted Ab-SA conjugate bound specifically to tumor cells, with unbound radiobiotin rapidly excreted by the kidneys. We have evaluated the safety of PRIT using an anti-CD45 Ab-SA conjugate followed by 90 Y-DOTA-biotin combined with fludarabine (FLU), 2 Gy total body irradiation (TBI) and matched allogeneic HCT for patients with advanced acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or high-risk myelodysplastic syndrome (MDS). Seven patients received trace labeled, dosimetric infusions of 0.7 mg/kg anti-CD45 Ab-SA followed 48 hours later by 1.3 mg/m 2 of 111 In-DOTA-biotin (5-10 mCi). The biodistribution of 111
In-DOTA-biotin was assessed by serial planar gamma camera imaging at multiple time points that revealed optimal targeting of leukemic target tissues. Five patients then received 0.7 mg/kg anti-CD45 Invasive fungal infections (IFI) are associated with a high mortality rate in patients undergoing hematopoietic stem cell transplantation (HSCT). However, with availability of new antifungal agents with lower toxicity profiles and implementation of reduced intensity transplants (RIT), patients with previously documented, proven or probable IFI are increasingly undergoing HSCT. Recognizing these practice changes, the clinical outcomes of patients with preexisting IFI, diagnosed prior to allogeneic HSCT, (n¼ 825) were compared to a similar cohort of patients from the same HSCT centers over the past decade without proven or probable pre-transplant IFI (n¼10,247), for outcomes of treatment related mortality (TRM), relapse rates, overall survival (OS), disease free survival (DFS) and the development of post-transplant IFI. Primary analysis focused on outcomes Conclusions: Documentation of pre-HSCT IFI is associated with lower DFS and OS after allogeneic HSCT. However, mortality is most influenced by patients with more advanced disease status than infectious etiologies. Treated pre-transplant IFI does not appear to be a contraindication to allogeneic HSCT.
Background: While CBT is a known risk factor for HHV-6 reactivation, the level of viremia associated with a high risk of HHV-6 encephalitis is not established and the association with CBT outcomes is controversial. Methods: We analyzed the nature of HHV-6 reactivation in 125 double-unit CB recipients who were transplanted for hematologic malignancies from 2/2006-3/2012. Viremia was measured by quantitative PCR of plasma HHV-6 DNA (lower detection limit 100 DNA copies/ml). Results: Of 125 patients (median age 42 years, range 1-69), 93 (74%) received myeloablative and 32 (26%) received non-myeloablative conditioning followed by 4-6/ 6 HLA-A,B antigen, -DRB1 allele matched CBT for the treatment of AML (n ¼ 43, 34%), ALL (n ¼ 24, 19%), MDS/ CML/ other leukemia (n ¼ 12, 10%), or lymphoma/ CLL (n ¼ 46, 37%). No patient received anti-thymocyte globulin (ATG). One-hundred and seventeen (94%) patients reactivated HHV-6 (median peak 7,600 copies/ml, range 100-160,000) at a median of 20 days (range 10-59). The median time to peak viremia was 23 days (range 12-62) and the median viremia duration was 8 days (range 1-60 days). Fifty-one patients (41% of total, 44% of viremic patients) developed HHV-6 > 10,000 copies/ml (median peak 31,200 copies/ml at 20 days, range 12-57). Only 6 patients (5% of total, 5% of viremic patients) had HHV-6 > 100,000 copies/ml (median peak 130,000 copies/ml at 19 days, range 14-29). HHV-6 encephalitis occurred in 2 patients (1.6%, peak viremias 13,000 and 118,000, respectively); 1 died from encephalitis and the other recovered with therapy. Four other viremic patients had HHV-6 isolated from bronchoalveolar lavage but did not meet criteria for HHV-6 pneumonia. Defining high level viremia as > 10,000 copies/ml in days 14-60, viremia was not associated with diagnosis or conditioning, engrafting unitrecipient HLA-match or TNC, CD34
Treating viremia as a time-dependent covariate in Cox regression analysis, no association was found between viremia and neutrophil or platelet engraftment. There was also no association between viremia and CMV reactivation, day 100 grade II-IV aGVHD, day 100 TRM, relapse, or overall survival. If high level viremia was defined as > 25,000 copies/ml (n ¼ 31, the highest peak viremia quartile days 14-60), no associations with CBT outcomes were detected. Finally, 24 patients had a second viremia (median onset day 49, range 100-27,300) without obvious sequelae.
Conclusions: Nearly all our CBT recipients reactivate HHV-6. While the incidence of end-organ disease is low, possibly due to our exclusion of ATG from the conditioning, our understanding of the significance of HHV-6 viremia is incomplete. We are currently evaluating anti-viral treatment responses, and ultimately a prospective trial is needed to better define the causality between HHV-6 viremia and transplantation outcomes, and to investigate the risk-benefits of pre-emptive therapy.
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